- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03070925
Prospective PuraPly™ AM Case Series Study
A Prospective, Observational Study of the Use of PuraPly™ Antimicrobial (PuraPly AM) in the Management of Wounds
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of the case series is to assess the ability of PuraPly AM to meet wound specific treatment goals including management of bioburden, support of granulation tissue formation, and support of wound closure. Patients will undergo clinical assessments and receive the standard of care as determined by the treating physician.
The case series is being undertaken to better understand PuraPly AM utilization and subsequent healing outcomes as well as to evaluate the effects of concomitant wound therapy on healing. Patient's participation may involve follow-up for up to 12 weeks following application of PuraPly AM.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
Lake Success, New York, United States, 11402
- Northwell Health, Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participant is at least 18 years of age
- Participant has read, understood and signed and Institutional Review Board (IRB) approved Informed Consent Form (ICF).
Participant has at least 1 wound appropriate for receiving PuraPly AM, including
- Partial and full-thickness wounds
- Pressure ulcers
- Venous ulcers
- Diabetic ulcers
- Chronic vascular ulcers
- Tunneled/undermined wounds
- Surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence)
- Trauma wounds (abrasions, lacerations, second-degree burns, skin tears)
- Draining wounds
Exclusion Criteria:
- Participant has a known sensitivity to porcine materials
- Participant has a third-degree burn
- Participant has a known sensitivity to polyhexamethylene biguanide hydrochloride (PHMB)
- Participants receiving concurrent treatment with other topical antimicrobials or skin substitute products
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in wound bed condition
Time Frame: 12 Weeks
|
As measured from change in status from baseline
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alisha Oropallo, MD, Northwell Health, Inc.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-AW-002-PPAM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgical Wounds
-
Universidade Federal FluminenseNot yet recruiting
-
G. d'Annunzio UniversityCompleted
-
University Health Network, TorontoCancer Care OntarioCompleted
-
Postgraduate Institute of Dental Sciences RohtakUnknownHealing Surgical WoundsIndia
-
KLOX Technologies Inc.CompletedSurgical WoundsCanada
-
KLOX Technologies Inc.CompletedPost-surgical WoundsCanada
-
NanoSHIFT LLCUnited States Department of DefenseWithdrawnDehisced Surgical WoundsUnited States
-
The Metis FoundationCompletedIncisions, SurgicalUnited States
-
Stony Brook UniversityWithdrawn
-
Ethicon, Inc.CompletedSurgical IncisionsBelgium, Germany, Sweden, United Kingdom
Clinical Trials on PuraPly™ Antimicrobial Wound Matrix
-
OrganogenesisContinuum Clinical Inc.CompletedSurgical Wounds | Pressure Ulcer | Venous Ulcer | Partial Thickness Wound | Diabetic Ulcer | Trauma Wounds | Draining Wounds | Chronic Vascular UlcerUnited States
-
OrganogenesisCompletedSurgical Wound | Pressure Ulcer | Venous Ulcer | Diabetic Ulcer | Trauma WoundUnited States
-
OrganogenesisTerminatedChronic Pressure UlcersUnited States
-
Integra LifeSciences CorporationSt Vincent's HospitalCompletedPressure Ulcer | Pressure Ulcers Stage III | Pressure Ulcer, Stage IVUnited States
-
Vomaris InnovationsCompletedWound Infection | Wound HealingUnited States
-
SerenaGroup, Inc.Sanara MedTechActive, not recruiting
-
Georgetown UniversityIntegra LifeSciences CorporationTerminatedDiabetes | Foot UlcerUnited States
-
Rochal Industries LLCThe University of Texas Health Science Center at San Antonio; Brooke Army Medical... and other collaboratorsNot yet recruiting
-
RenovoDermNorthwell Health; University of Wisconsin, MadisonNot yet recruiting
-
SerenaGroup, Inc.DSM Biomedical, Inc.Completed